Lupkynis is $92,000 a yr ( before discounts and rebates ).
It has a Tier 5 rating at Kaiser … which means if you’re an LN patient at Kaiser and want Lupkynis…. You pay for it
How many LN patients are willing to pay $92k a year.
How about at the rumored discounted Medicare / Medicaid price of $65,000 ?
Cosa. Suggest you chk the various formularies to see where Lupkynis is priced .
Some Nephrologist like Lupkynis because of its fast action and fact that they can quickly taper the steriods that are prescribed with it . Patients had the steriods .
But if the insurer places Lupkynis on a high tier which requires a high patient copay … patients don’t maintain their scripts
By the way , this high initial price is not unusual when CO’s first launch new drugs .
Amgen ( I think ) launched their PCSK9 ( for lowering very high LDL cholesterol) at around $12,000 a yr .
Insurer’s placed it at a high tier ( like Lupkynis) which meant patients had to pay close to full price … which few did
2 yrs later Amgen agreed to lower their WAC ( insurer acquisition cost ) to around $4,500’…. Insurers lowered the tier rating and patients now can get it for around $100-$150 a month co pay .
So AUPH has to drastically cut their WAC to move Lupkynis. Even then patients will only use it until a similar drug comes along that doesn’t need them to also take steriods .
P2 data on that similar drug that shall not be named ..due within next 8 weeks
Kiwi
News 
Market Data 
Discover 
